Payment overview · 2025
General Payments
$852.39
38 reported records · 18 companies
Healthcare provider profile · identity verified
Ruby J Parveen, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BAYTOWN, TX · NPI 1457540882
Verified facts
What the public records show
CMS Open Payments records show Ruby J Parveen, MD received $852.39 in general payments during 2025 across 38 reported records.
UCB, Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Qulipta by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $174.72 | 20.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $154.90 | 18.2% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $99.60 | 11.7% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $63.94 | 7.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $45.53 | 5.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $38.18 | 4.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $33.70 | 4.0% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $33.14 | 3.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $30.64 | 3.6% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.35 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.17 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.16 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.90 | 2.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.76 | 2.3% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $18.02 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.43 | 2.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.98 | 2.0% | 1 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $14.27 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $852.39 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $99.60 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $87.33 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.03 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $83.32 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $63.94 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $58.99 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $42.18 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $33.70 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $33.14 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $32.41 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $30.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| Home PI Undivided Normalized: home pi undivided |
Device | Philips North America LLC | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 206 | 46 |
| Donepezil Hcl | Donepezil Hcl | 185 | 51 |
| Memantine Hcl | Memantine Hcl | 161 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 23 |
| Levetiracetam | Levetiracetam | 91 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 20 |
| Buspirone Hcl | Buspirone Hcl | 76 | 19 |
| Primidone | Primidone | 74 | 21 |
| Trazodone Hcl | Trazodone Hcl | 60 | 19 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Mirtazapine | Mirtazapine | 49 | 18 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 48 | suppressed |
| Pregabalin | Pregabalin | 47 | 15 |
| Sertraline Hcl | Sertraline Hcl | 46 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 45 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Rivastigmine | Rivastigmine | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Topiramate | Topiramate | 35 | 14 |
| Entacapone | Entacapone | 34 | suppressed |
| Amantadine | Amantadine Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Kesimpta Pen | Ofatumumab | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Qulipta | Atogepant | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Armodafinil | Armodafinil | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Austedo | Deutetrabenazine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Keppra | Levetiracetam | 15 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $852.39 · 38 records | UCB, Inc. | AIRSENSE, AUSTEDO XR, BOTOX, Briviact, Home PI Undivided, INFINITY, INSPIRE, KESIMPTA, LINQ II, Leqembi, MOUNJARO, Nayzilam, QULIPTA, Qelbree, REXULTI, Rystiggo, Symbravo, UBRELVY, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYALEV, VYEPTI, VYVGART HYTRULO, XYWAV, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error